The IMI PROTECT Project: Purpose, Organizational Structure, and Procedures

Mar-16

AUTHORS : Prof Olaf H. Klungel, Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Universiteitsweg 99, PO Box 80082, 3584CG Utrecht, the Netherlands – Email: O.H.Klungel@uu.nl – Profile: https://www.uu.nl/staff/OHKlungel – Not sure if contact Dr Robert Reynolds still works at Pfizer (Department of Epidemiology, WorldwideResearch and Development, Pﬁzer, Inc., 235 East 42nd Street, 219-9-01, NewYork, New York, USA – Email: robert.reynolds@pﬁzer.com)

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 25(S1):5-10

DOI : 10.1002/pds.3933

The IMI PROTECT Project: Purpose, Organizational Structure, and Procedures

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study